Lysophosphatidic acid receptor isoforms expression in prostate cancer cells is differentially regulated by the CYP17A1 inhibitor abiraterone and depends on the androgen receptor

Stope, Matthias B.; Mandelkow, Robert; Brünnert, Daniela; Weiß, Martin; Burchardt, Martin

doi:10.18282/amor.v2.i1.83

Cited by 3 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, one report suggested that LPAR1 expression in androgen receptorexpressing prostate cancer cells is regulated in an androgen-dependent manner [51]. In comparison with LPARs 1-3, little is known about LPAR4 and LPAR5 as they are expressed at low levels in prostate cancer cells [52].…”

Section: Prostate Cancermentioning

confidence: 99%

Lysophosphatidic Acid Signaling in Cancer Cells: What Makes LPA So Special?

Balijepalli

Sitton

Meier

2021

Cells

View full text Add to dashboard Cite

Lysophosphatidic acid (LPA) refers to a family of simple phospholipids that act as ligands for G protein-coupled receptors. While LPA exerts effects throughout the body in normal physiological circumstances, its pathological role in cancer is of great interest from a therapeutic viewpoint. The numerous LPA receptors (LPARs) are coupled to a variety of G proteins, and more than one LPAR is typically expressed on any given cell. While the individual receptors signal through conventional GPCR pathways, LPA is particularly efficacious in stimulating cancer cell proliferation and migration. This review addresses the mechanistic aspects underlying these pro-tumorigenic effects. We provide examples of LPA signaling responses in various types of cancers, with an emphasis on those where roles have been identified for specific LPARs. While providing an overview of LPAR signaling, these examples also reveal gaps in our knowledge regarding the mechanisms of LPA action at the receptor level. The current understanding of the LPAR structure and the roles of LPAR interactions with other receptors are discussed. Overall, LPARs provide insight into the potential molecular mechanisms that underlie the ability of individual GPCRs (or combinations of GPCRs) to elicit a unique spectrum of responses from their agonist ligands. Further knowledge of these mechanisms will inform drug discovery, since GPCRs are promising therapeutic targets for cancer.

show abstract

Section: Prostate Cancermentioning

confidence: 99%

Lysophosphatidic Acid Signaling in Cancer Cells: What Makes LPA So Special?

Balijepalli

Sitton

Meier

2021

Cells

View full text Add to dashboard Cite

show abstract

“…The current issue of AMOR features an interesting article by Mandelkow and co-workers [5] , which explores the in vitro activity of abiraterone acetate against the androgen receptor in prostate cancer cells and this may lead to the invention of innovative methods to help personalize the administration of this drug. Advocating the use of personalized therapy in the treatment of prostate cancer should be the focus of basic and clinical researchers alike as this should, in principle, improve the prognosis of cancer patients.…”

Section: Receivedmentioning

confidence: 99%